<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Xu J</submitter><funding>National Natural Science Foundation of China</funding><funding>Chinese Academy of Medical Science (CAMS) Innovation Fund for Medical Sciences</funding><pagination>237</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12183871</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>24(1)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>Coronary angiography remains the gold standard for diagnosing coronary artery disease (CAD), but its invasive nature limits its applicability for widespread screening. Identifying non-invasive molecular markers could improve CAD classification and risk assessment.&lt;h4>Methods&lt;/h4>We employed 5hmC-Seal technology to generate genome-wide 5-hydroxymethylcytosine (5hmC) profiles from plasma cell-free DNA (cfDNA) in 724 CAD patients, stratified into stable CAD (sCAD), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI) groups. Using machine learning algorithms, we identified inflammation-related 5hmC modifications associated with disease severity and constructed a classification model based on key hydroxymethylated markers. The model</pubmed_abstract><journal>Cardiovascular diabetology</journal><pubmed_title>Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease.</pubmed_title><pmcid>PMC12183871</pmcid><funding_grant_id>2016-I2M-1-009</funding_grant_id><funding_grant_id>82192902</funding_grant_id><funding_grant_id>82204399</funding_grant_id><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>He C</pubmed_authors><pubmed_authors>Li J</pubmed_authors><pubmed_authors>Zhang J</pubmed_authors><pubmed_authors>Chen L</pubmed_authors><pubmed_authors>Chen H</pubmed_authors><pubmed_authors>Zhang L</pubmed_authors><pubmed_authors>Li L</pubmed_authors><pubmed_authors>Xu J</pubmed_authors><pubmed_authors>Yuan J</pubmed_authors><pubmed_authors>Zhao X</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Yang W</pubmed_authors><pubmed_authors>Yang Y</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Lu J</pubmed_authors><pubmed_authors>Tian T</pubmed_authors><pubmed_authors>Gao X</pubmed_authors><pubmed_authors>Lin J</pubmed_authors><pubmed_authors>Wu Y</pubmed_authors><pubmed_authors>Dong C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Inflammation-related 5-hydroxymethylation signatures as markers for clinical presentations of coronary artery disease.</name><description>&lt;h4>Background&lt;/h4>Coronary angiography remains the gold standard for diagnosing coronary artery disease (CAD), but its invasive nature limits its applicability for widespread screening. Identifying non-invasive molecular markers could improve CAD classification and risk assessment.&lt;h4>Methods&lt;/h4>We employed 5hmC-Seal technology to generate genome-wide 5-hydroxymethylcytosine (5hmC) profiles from plasma cell-free DNA (cfDNA) in 724 CAD patients, stratified into stable CAD (sCAD), non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI) groups. Using machine learning algorithms, we identified inflammation-related 5hmC modifications associated with disease severity and constructed a classification model based on key hydroxymethylated markers. The model</description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Jun</publication><modification>2026-04-25T03:27:42.782Z</modification><creation>2026-04-25T03:22:11.762Z</creation></dates><accession>S-EPMC12183871</accession><cross_references><pubmed>40551101</pubmed><doi>10.1186/s12933-025-02749-x</doi></cross_references></HashMap>